A share price of Heron Therapeutics Inc [HRTX] is currently trading at $1.60, up 4.58%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRTX shares have gain 1.27% over the last week, with a monthly amount glided 31.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on June 13, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $7. Previously, CapitalOne started tracking the stock with Overweight rating on April 23, 2024, and set its price target to $6. On March 13, 2024, Needham reiterated its Buy rating and revised its price target to $5 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $24 on May 27, 2020. Needham reiterated its recommendation of a Buy and reduced its price target to $48 on February 20, 2020. Needham reiterated a Buy rating for this stock on January 16, 2019, and downed its price target to $64. In a note dated April 05, 2018, Evercore ISI initiated an Outperform rating and provided a target price of $56 on this stock.
Heron Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.04 and $3.93. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $1.60 at the most recent close of the market. An investor can expect a potential return of 337.5% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
Trailing Twelve Months sales for Heron Therapeutics Inc [NASDAQ:HRTX] were 137.74M which represents 4.38% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is 0.77 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5367 points at the first support level, and at 1.4733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6567, and for the 2nd resistance point, it is at 1.7133.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Heron Therapeutics Inc [NASDAQ:HRTX] is 2.28. As well, the Quick Ratio is 1.74, while the Cash Ratio is 0.3. Considering the valuation of this stock, the price to sales ratio is 1.77.
